Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;20(1):54-59.
doi: 10.1016/j.jval.2016.08.727. Epub 2016 Oct 21.

Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice

Marc B Rosenman  1 , Brian Decker  2 , Kenneth D Levy  2 , Ann M Holmes  3 , Victoria M Pratt  4 , Michael T Eadon  2
Affiliations

Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice

Marc B Rosenman et al. Value Health. 2017 Jan.

Abstract

Objectives: Implementing new programs to support precision medicine in clinical settings is a complex endeavor. We describe challenges and potential solutions based on the Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health-one of six sites supported by the Implementing GeNomics In pracTicE network grant of the National Institutes of Health/National Human Genome Research Institute. INGenious is an implementation of a panel of genomic tests.

Methods: We conducted a descriptive case study of the implementation of this pharmacogenomics program, which has a wide scope (14 genes, 27 medications) and a diverse population (patients who often have multiple chronic illnesses, in a large urban safety-net hospital and its outpatient clinics).

Challenges: We placed the clinical pharmacogenomics implementation challenges into six categories: patient education and engagement in care decision making; clinician education and changes in standards of care; integration of technology into electronic health record systems; translational and implementation sciences in real-world clinical environments; regulatory and reimbursement considerations, and challenges in measuring outcomes. A cross-cutting theme was the need for careful attention to workflow. Our clinical setting, a safety-net health care system, presented some distinctive challenges. Patients often had multiple chronic illnesses and sometimes were taking more than one pharmacogenomics-relevant medication. Reaching patients for recruitment or follow-up was another challenge.

Conclusions: New, large-scale endeavors in health care are challenging. A description of the challenges that we encountered and the approaches that we adopted to address them may provide insights for those who implement and study innovations in other health care systems.

Keywords: clinical decision support; electronic health records; pharmacogenomics; precision medicine.

PubMed Disclaimer

References

    1. ) U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/... [Accessed April 5, 2016].
    1. ) Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte -an update of guidelines. Clin Pharmacol Ther 2011;89:662–73. - PubMed
    1. ) Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011;89:464–7. - PMC - PubMed
    1. ) Clinical Pharmacogenetics Implementation Consortium. CPIC™ Genes-Drugs. Available from: https://cpicpgx.org/genes-drugs/ [Accessed April 5, 2016].
    1. ) Lam YWF. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol 2013;2013:641089. - PMC - PubMed

MeSH terms